Novo Nordisk Profit Beats Estimates as Victoza Sales Rise
This article is for subscribers only.
Novo Nordisk A/S, the world’s largest insulin maker, reported a 3.9 percent gain in second-quarter profit, helped by sales of insulins and the Victoza diabetes treatment.
Net income climbed to 6.99 billion kroner ($1.25 billion) from 6.73 billion kroner a year earlier, the Bagsvaerd, Denmark-based company said today in a statement. That beat a 6.88 billion-kroner average estimate of 18 analysts surveyed by Bloomberg. The drugmaker reiterated full-year forecasts in local currencies and said data from a trial of its Tresiba insulin will be available sooner than it expected.